benserazide has been researched along with Parkinson Disease, Postencephalitic in 4 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Parkinson Disease, Postencephalitic: Parkinsonism following encephalitis, historically seen as a sequella of encephalitis lethargica (Von Economo Encephalitis). The early age of onset, the rapid progression of symptoms followed by stabilization, and the presence of a variety of other neurological disorders (e.g., sociopathic behavior; TICS; MUSCLE SPASMS; oculogyric crises; hyperphagia; and bizarre movements) distinguish this condition from primary PARKINSON DISEASE. Pathologic features include neuronal loss and gliosis concentrated in the MESENCEPHALON; SUBTHALAMUS; and HYPOTHALAMUS. (From Adams et al., Principles of Neurology, 6th ed, p754)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Subsequently they were treated with either a mean dosage of 444 mg levodopa and benserazide (47 patients) or a combination of a mean of 298 mg levodopa and benserazide plus 17 mg bromocriptine (32 patients)." | 2.65 | [Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study]. ( Fischer, PA; Majer, M; Przuntek, H; Welzel, D, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Evrard, F | 1 |
| Dupuis, M | 1 |
| Muller, T | 1 |
| Jacquerye, P | 1 |
| Fischer, PA | 1 |
| Przuntek, H | 1 |
| Majer, M | 1 |
| Welzel, D | 1 |
| Barbeau, A | 1 |
| Rinne, UK | 1 |
| Sonninen, V | 1 |
| Siirtola, T | 1 |
1 trial available for benserazide and Parkinson Disease, Postencephalitic
| Article | Year |
|---|---|
[Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
Topics: Aged; Benserazide; Bromocriptine; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combinati | 1984 |
3 other studies available for benserazide and Parkinson Disease, Postencephalitic
| Article | Year |
|---|---|
[Isolated pulmonary hypertension and pergolide].
Topics: Antiparkinson Agents; Benserazide; Benzothiazoles; Blood Pressure; Catechols; Dyspnea; Echocardiogra | 2008 |
Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Evaluation; Humans; Levod | 1975 |
Plasma concentration of levodopa in patients with Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Benserazide; Dihydroxyphenylalanine; Drug Combinations; Female; H | 1973 |